MedOncMD

To provide the information your oncologist is not telling you or doesn't have the time to!

  • Home
  • Magazine
  • Blog
    • The essentials
    • Art of Oncology
    • Prevention and Healthy Lifestyle
    • Research Advances
    • Navigation Corner
    • Video Library
  • Navigation Corner
  • Meet and Greet
    • About Dr Thomas
    • About Dr Landau
  • Ask MedOncMD?
  • Keep in Touch!
Advancements in Hodgkin's Lymphoma

Advancements in Hodgkin’s Lymphoma

Traditional Treatment Approaches for Hodgkin’s Lymphoma Lymphomas encompass a diverse group of blood cancers, with various types and treatment approaches depending on factors such as lymphoma subtype, origin, and aggressiveness. One particular lymphoma subtype with unique treatment options is Hodgkin’s lymphoma. Traditionally, in the United States, Hodgkin’s lymphoma has been treated with a chemotherapy combination …

Read On »

CAR-T and Bispecific Antibodies ii

CAR-T and Bispecific Antibodies-By Dr Landau

We are currently in an era where we’re shifting from traditional chemotherapies to leveraging the body’s immune system. CAR-T and bispecific antibodies are two innovative approaches to achieve this.

Grading Drug Toxicities

Grading Drug Toxicities

In the realm of oncology trials, we employ a severity rating system known as the Grade scale to assess toxicities. This scale helps us gauge whether a patient should modify or discontinue their treatment. The Grade scale consists of five points, ranging from mild toxicities to life-threatening ones.

Uveal melanoma, a rare and aggressive form of eye cancer, has just witnessed a groundbreaking development in its treatment landscape. The Food and Drug Administration (FDA) recently granted approval to the HEPZATO KIT, an innovative liver-directed therapy that offers new hope to adult patients with uveal melanoma and unresectable hepatic metastases.

A Breakthrough in Uveal Melanoma Treatment: HEPZATO KIT

Uveal melanoma, a rare and aggressive form of eye cancer, has just witnessed a groundbreaking development in its treatment landscape. The Food and Drug Administration (FDA) recently granted approval to the HEPZATO KIT, an innovative liver-directed therapy that offers new hope to adult patients with uveal melanoma and unresectable hepatic metastases.

Navigating a clinical trial: How do I get started?

The choice to participate in a clinical trial may sound scary or it may sound exciting but if you are considering it, the real question is what happens next? Below I will help you navigate through the process of getting onto a clinical trial by answering some of the questions that I get from patients who are going through this process.

CLN-617-001: A Promising New Study Combines Intratumoral Therapy with Immune Therapy 

Intratumoral therapies is another class of immunotherapeutics that I often consider especially for folks with limited skin or nodal disease or perhaps deeper oligometastatic disease. I have cutaneous malignancies patients with Melanoma, Cutaneous SCC, Merkel cell and Kaposi sarcomas that have responded to local intratumoral therapies. We’ve seen viral agents like FDA approved TVEC, RP1, …

Read On »

Myelodysplasia (MDS) is a bone marrow syndrome characterized by the presence of unhealthy (dysplastic) stem cells that displace the healthy ones, disrupting their ability to mature and develop properly. These healthy stem cells are responsible for generating essential components like red blood cells (which transport oxygen), white blood cells (crucial for fighting infections), and platelets (important for clotting). However, the unhealthy cells can suppress the function of the healthy ones, leading to various dysfunctions.

Assisting Red Blood Cell Growth

Myelodysplasia (MDS) is a bone marrow syndrome characterized by the presence of unhealthy (dysplastic) stem cells that displace the healthy ones, disrupting their ability to mature and develop properly. These healthy stem cells are responsible for generating essential components like red blood cells (which transport oxygen), white blood cells (crucial for fighting infections), and platelets (important for clotting). However, the unhealthy cells can suppress the function of the healthy ones, leading to various dysfunctions.

Dacarbazine, referred to as DTIC, is a chemotherapy administered intravenously every 3 weeks. Unesbulin is a novel, oral drug, administered twice weekly and is currently being researched in the treatment of advanced solid tumors. In this case, it is being studied in conjunction with DTIC for treatment of metastatic or unresectable, relapsed or refractory Leiomyosarcoma. Participants can be randomized to receive either DTIC with Unesbulin or DTIC with placebo.  

About Leiomyosarcoma – A look at new advances by Chloe Caldwell

In terms of cancer diagnoses, the more common ones we hear of are cancers such as Leukemia, Lymphoma, melanoma, and breast cancer. But what about Leiomyosarcoma?

Leiomyosarcoma is a rare and aggressive form of cancer that develops in the smooth muscles of the body (i.e. intestines, stomach, uterus, blood vessels).

Facing the Unknown: Decoding a Mysterious Axillary Adenopathy

Navigating the complex realm of oncology often involves a blend of clinical expertise, investigative curiosity, and intuitive sensitivity. A recent encounter with a patient, previously diagnosed with a sizable axillary adenopathy considered “benign”, reinforces the necessity of approaching medical puzzles with an open mind and meticulous attention to detail. Earlier this year, a patient was …

Read On »

Benign Hematology: Beyond Cancer Concerns

Hematologists play a pivotal role in addressing various non-cancerous hematological conditions, alleviating patient concerns about being associated solely with cancer care. Many patients are unaware that hematologists are involved in treating a range of benign conditions, including: 1. Anemia: Anemia, characterized by low hemoglobin levels, can stem from various causes such as iron deficiency, inadequate …

Read On »

  • Previous
  • Page 1
  • …
  • Page 14
  • Page 15
  • Page 16
  • Page 17
  • Page 18
  • …
  • Page 23
  • Next

Recent Posts

  • The Story Behind the Logo: Building the Bridge, Stone by Stone
  • Remembering Dr. Craig Kitchens: The Legacy of a Great Physician
  • Six Months Later: Rediscovering Balance Through Locum Life and New Ventures
  • When Delay Becomes Harm: A Clinician’s Reflection on Timely Cancer Care
  • Understanding Disability in Oncology: A Clinician’s Perspective

Categories

  • Art of Oncology (78)
  • Current News (12)
  • Immunotherapy News (9)
  • Navigation Corner (6)
  • Prevention and Healthy Lifestyle (18)
  • Research Advances (108)
    • Clinical Trials (43)
    • Immunotherapy (29)
    • New Treatments and Therapies (42)
  • The essentials (41)
    • Radiology (4)
  • Travel Health (1)
  • Uncategorized (10)
  • Varied Cancer Perspectives (114)
    • Biliary tract cancer (3)
    • Bladder Cancer (3)
    • Breast Cancer (10)
    • Cervical Cancer (2)
    • CNS Cancers (1)
    • Colorectal cancer (13)
    • Esophageal Cancer (2)
    • Gastric cancer (6)
    • Hepatic Tumors (1)
    • Leiomyosarcoma (2)
    • Leukemia (2)
    • Lung Cancer (10)
    • Lymphoma (3)
    • Melanoma (28)
    • Multiple Myeloma (3)
    • Neuroendocrine cancer (2)
    • Ovarian Cancer (3)
    • Pancreatic Cancer (5)
    • Prostate Cancer (4)
    • Sarcoma (2)
    • Sickle Cell Disease (4)
    • Skin Cancer (7)
    • Thyroid cancer (1)
    • Urothelial Cancer (1)
  • Video (2)
  • Weekly Newsletter (6)

Get in touch!

  • Facebook
  • Instagram
  • TikTok
  • LinkedIn


Meet the authors

Dr. Sajeve Thomas
Dr Daniel Landau


Subscribe


  • Home
  • Magazine
  • Blog
    • The essentials
    • Art of Oncology
    • Prevention and Healthy Lifestyle
    • Research Advances
    • Navigation Corner
    • Video Library
  • Navigation Corner
  • Meet and Greet
    • About Dr Thomas
    • About Dr Landau
  • Ask MedOncMD?
  • Keep in Touch!
© 2025 MedOncMD. Minimal Theme by SPYR
✕
  • Home
  • Magazine
  • Blog
    • The essentials
    • Art of Oncology
    • Prevention and Healthy Lifestyle
    • Research Advances
    • Navigation Corner
    • Video Library
  • Navigation Corner
  • Meet and Greet
    • About Dr Thomas
    • About Dr Landau
  • Ask MedOncMD?
  • Keep in Touch!